Vir Biotechnology to Participate in the H.C. Wainwright 5th Annual Viral Hepatitis Virtual Conference

10/3/24 4:00:00 PM ET

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Get the next $VIR alert in real time by email

Vir Biotechnology, Inc. (NASDAQ:VIR) today announced that Mark Eisner, M.D., M.P.H., Executive Vice President and Chief Medical Officer, is scheduled to participate in a fireside chat at the H.C. Wainwright 5th Annual Viral Hepatitis Virtual Conference on Tuesday, October 8, at 10:00 a.m. PT / 1:00 p.m. ET.

A live webcast of the fireside chat will be made available under Events & Presentations in the Investors section of the Vir website at www.vir.bio and will be archived there for 30 days.

About Vir Biotechnology, Inc.

Vir Biotechnology, Inc. is a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for serious infectious diseases and cancer. Vir's clinical-stage portfolio includes infectious disease programs for chronic hepatitis delta and chronic hepatitis B infections, in addition to multiple oncology programs. Vir also has a preclinical portfolio of programs across a range of other infectious diseases and oncologic malignancies. Vir routinely posts information that may be important to investors on its website.

View source version on businesswire.com: https://www.businesswire.com/news/home/20241003019939/en/

Get the next $VIR alert in real time by email

Recent Analyst Ratings for

$VIR

Date	Price Target	Rating	Analyst
1/29/2024	$23.00 → $9.00	Overweight → Neutral	JP Morgan
9/8/2023	$23.00 → $14.00	Buy → Neutral	BofA Securities
3/6/2023	$35.00 → $34.00	Neutral → Overweight	JP Morgan
2/21/2023	$41.00 → $53.00	Neutral → Buy	Goldman
1/27/2023	$18.00 → $30.00	Underweight → Equal-Weight	Morgan Stanley
9/14/2022	$40.00	Outperform	SVB Leerink
9/9/2022	$15.00	Underweight	Morgan Stanley
3/3/2022	$36.00 → $28.00	Underperform → Neutral	Baird

More analyst ratings

Vir Biotechnology to Participate in the H.C. Wainwright 5th Annual Viral Hepatitis Virtual Conference

Chat with this insight

Recent Analyst Ratings for $VIR

$VIR Press Releases

Fastest customizable press release news feed in the world

Vir Biotechnology Presents Positive Chronic Hepatitis Delta Clinical Trial Data and Announces Initiation of Phase 3 Registrational Program

Vir Biotechnology Receives Positive Opinion on Orphan Drug Designation for Tobevibart and Elebsiran in Chronic Hepatitis Delta from European Medicines Agency

Vir Biotechnology Announces Positive End-of-Treatment Results for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B from the MARCH Study at AASLD The Liver Meeting

$VIR Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Vir Biotechnology downgraded by JP Morgan with a new price target

Vir Biotechnology downgraded by BofA Securities with a new price target

Vir Biotechnology upgraded by JP Morgan with a new price target

$VIR Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

EVP & Chief Financial Officer O'Byrne Jason was granted 75,000 units of Common Stock (SEC Form 4)

EVP and General Counsel De Verneuil Vanina sold $44,454 worth of Common Stock (4,397 units at $10.11), decreasing direct ownership by 7% to 56,973 units (SEC Form 4)

EVP and General Counsel De Verneuil Vanina sold $32,332 worth of Common Stock (3,750 units at $8.62), decreasing direct ownership by 6% to 61,370 units (SEC Form 4)

$VIR SEC Filings

SEC Form 10-Q filed by Vir Biotechnology Inc.

Vir Biotechnology Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

Vir Biotechnology Inc. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

$VIR Market Insights

Live Market Insights

Vir Biotechnology's Hepatitis Delta Drug Combo Receives FDA Clearance and Fast Track Status

Morgan Stanley Maintains Equal-Weight on Vir Biotechnology, Raises Price Target to $15

Why Is Infectious Disease-Focused Vir Biotechnology Stock Trading Higher On Wednesday?

$VIR Financials

Live finance-specific insights

$VIR Large Ownership Changes

This live feed shows all institutional transactions in real time.

$VIR Leadership Updates

Live Leadership Updates

Vir Biotechnology Presents Positive Chronic Hepatitis Delta Clinical Trial Data and Announces Initiation of Phase 3 Registrational Program

Vir Biotechnology Receives Positive Opinion on Orphan Drug Designation for Tobevibart and Elebsiran in Chronic Hepatitis Delta from European Medicines Agency

Vir Biotechnology Announces Positive End-of-Treatment Results for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B from the MARCH Study at AASLD The Liver Meeting

Amendment: SEC Form SC 13G/A filed by Vir Biotechnology Inc.

SEC Form SC 13G/A filed by Vir Biotechnology Inc. (Amendment)

SEC Form SC 13G/A filed by Vir Biotechnology Inc. (Amendment)

Vir Biotechnology Appoints Jason O'Byrne as Chief Financial Officer

Lineage Announces Appointment of Charlotte Hubbert, Ph.D., as Vice President of Corporate Development

Vir Biotechnology Appoints Jennifer Towne, Ph.D., as Executive Vice President and Chief Scientific Officer

Recent Analyst Ratings for
$VIR

$VIR
Press Releases

$VIR
Analyst Ratings

$VIR
Insider Trading

$VIR
SEC Filings

$VIR
Market Insights

$VIR
Financials

$VIR
Large Ownership Changes

$VIR
Leadership Updates